• Nicoleta Stoicea, Daric Russell, Greg Weidner, Michael Durda, Nicholas C Joseph, Jeffrey Yu, and Sergio D Bergese.
• Department of Anesthesiology, The Ohio State University Wexner Medical Center Columbus, OH, USA.
• Front Pharmacol. 2015 Jan 1; 6: 104.

AbstractChronic pain patients receiving opioid drugs are at risk for opioid-induced hyperalgesia (OIH), wherein opioid pain medication leads to a paradoxical pain state. OIH involves central sensitization of primary and secondary afferent neurons in the dorsal horn and dorsal root ganglion, similar to neuropathic pain. Gabapentin, a gamma-aminobutyric acid (GABA) analog anticonvulsant used to treat neuropathic pain, has been shown in animal models to reduce fentanyl hyperalgesia without compromising analgesic effect. Chronic pain patients have also exhibited lower opioid consumption and improved pain response when given gabapentin. However, few human studies investigating gabapentin use in OIH have been performed in recent years. In this review, we discuss the potential mechanisms that underlie OIH and provide a critical overview of interventional therapeutic strategies, especially the clinically-successful drug gabapentin, which may reduce OIH.

6 keywords...

hide…